Detalles de la búsqueda
1.
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
Antimicrob Agents Chemother;
63(1)2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30397067
2.
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.
Antimicrob Agents Chemother;
63(10)2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31332068
3.
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
Antimicrob Agents Chemother;
62(8)2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29784852
4.
Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.
Antimicrob Agents Chemother;
61(9)2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28696231
5.
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
J Antimicrob Chemother;
71(4): 862-70, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26702925
6.
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother;
59(1): 372-80, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25367904
7.
Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia.
Infect Dis Clin Pract (Baltim Md);
23(1): 39-43, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25574117
8.
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
Antimicrob Agents Chemother;
58(2): 885-91, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24277021
9.
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.
Antimicrob Agents Chemother;
57(12): 6348-50, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24041902
10.
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother;
56(5): 2231-6, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22314524
11.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Clin Infect Dis;
52(1): 31-40, 2011 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21148517
12.
Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
J Antimicrob Chemother;
66 Suppl 3: iii53-9, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482570
13.
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
J Antimicrob Chemother;
71(6): 1748-9, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27076104
14.
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
J Antimicrob Chemother;
66 Suppl 3: iii45-51, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482569
15.
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
J Antimicrob Chemother;
66 Suppl 3: iii19-32, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482566
16.
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Clin Infect Dis;
51(6): 641-50, 2010 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20695801
17.
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Clin Infect Dis;
51(12): 1395-405, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21067350
18.
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Int J Antimicrob Agents;
53(6): 830-837, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30716446
19.
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Clin Infect Dis;
46(11): 1683-93, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18444791
20.
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Int J Antimicrob Agents;
50(2): 247-251, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28599867